Prescription Justice
BLOG POSTS

30
Jan
2017

Prescription Justice – The Name Speaks for Itself

We are proud to announce that we have changed our organization’s (DBA) name from Prescription Justice Action Group to Prescription Justice, which is a simpler expression of our core position: making prescription drugs affordable is an issue of justice for Americans and we will help them obtain it.

21
Jan
2017

Sanders, Klobuchar Importation Amendment Defeated but Future Bipartisanship Seems Possible

Last week, Senators Bernie Sanders (I-VT) and Amy Klobuchar (D-MN) proposed an amendment (S.A. 178) to the Senate Budget Reconciliation bill that would allow individuals, pharmacies and wholesalers to import prescription medications from Canada and other countries with a valid prescription from a U.S. provider. The amendment took place during a 7-hour vote-a-rama in which more than 150 amendments were considered and voted on for a brief ten minutes. The amendment failed 52-46, with 13 Democrats voting against it. While the measure failed to pass, it surprisingly garnered support from 12 Republicans including Senators Ted Cruz and Rand Paul. It’s worth noting that Senators Chuck Schumer (D-NY) and Kristen Gillibrand (D-NY) voted against the Dorgan-Snowe importation amendment in 2009, voted yes this time around.

06
Jan
2017

Value-Based Pharmaceutical Pricing: Tying Drug Prices to Health Outcomes

Value-based pharmaceutical pricing, aimed at achieving better value for pharmaceutical spending and lowering drug prices, while maintaining innovation, is a concept that is gaining traction. In the U.S., prescription drug prices are set by pharmaceutical companies to maximize

12
Dec
2016

Delinking Pharmaceutical R & D Costs to Promote Innovation and Access to Affordable Medicines

The pharmaceutical industry often defends shameful price gouging of consumers by arguing that their high profits fund the research and development of tomorrow’s new miracle cures. There is robust debate about the degree to which lowering drug prices would hurt pharmaceutical innovation. The current system holds consumers and governments hostage to pharmaceutical company business models in a manner that is inherently unethical. Think of the cancer patient who has to shell out $30,000 in co-insurance to live, and if not, then die. The concept and practice of “delinkage,” in which the invention of new medicines is delinked from high drug prices transcends this old debate and envisions a brighter more humane future…one with robust pharmaceutical innovation.

17
Nov
2016

Will President Trump Bring Justice to Americans Who Can’t Afford Medication?

Last year, U.S. spending on prescription drugs was at a record breaking $425 billion before discounts, and is expected to rise by 22% annually over the next five years, which is 400%, or over $600 billion by 2020. As Donald Trump is sworn in as the 45th president of the United States, Americans across the country concerned with the soaring costs of prescription medications, will be looking to President Trump and Congress for solutions to address this national crisis. President-Elect Trump’s top priority for healthcare reform is to repeal the Affordable Care Act, but most Americans are more concerned about prescription drug prices than Obamacare.

← Previous
1
…
9
10
11
12 (current)
13
14
15
Next →

Tags

Stay informed about news and advocacy centered on the crisis of high drug prices